AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis
Abroad (travel likely)Recruiting
Conditions
Ulcerative Colitis (UC) · Inflammatory Bowel Disease (IBD) · Colitis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Ege University, Izmir, Turkey (Türkiye)
Study leads
Varol TUNALI
Principal Investigator
Enbiosis Biotechnology Limited